[A18-68] Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)
Last updated 04.04.2019
Project no.:
A18-68
Commission:
Commission awarded on 12.10.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Vitreomacular traction, including when associated with macular hole of diameter ≤ 400 microns
Added benefit not proven for mild or severe symptoms
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2019-01-15.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-20 | Ocriplasmin (vitreomacular traction) - Addendum to Commission A18-68 | Commission completed |
| A13-20 | Ocriplasmin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2019-04-04 A G-BA decision was published.